Future studies will need to focus on the generation and efficacy of recombinant forms of LIMA1 for the treatment of prostate cancer both in vitro and in vivo, thus facilitating the identification of new “druggable” therapeutic targets for the treatment of metastatic prostate cancer to help design new therapeutic strategies. The gene discussed is LIMA1; the disease is Familial prostate cancer.